DiaMedica Therapeutics Inc (NASDAQ:DMAC) Short Interest Update
DiaMedica Therapeutics Inc (NASDAQ:DMAC) saw a large decrease in short interest during the month of July. As of July 15th, there was short interest totalling 34,200 shares, a decrease of 50.8% from the June 15th total of 69,500 shares. Based on an average daily trading volume, of 110,100 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.4% of the company’s stock are short sold.
DMAC has been the topic of several research analyst reports. Zacks Investment Research upgraded Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Tuesday, July 16th. Dougherty & Co restated a “buy” rating on shares of Iteris in a research note on Tuesday, April 30th. Finally, Craig Hallum raised their price objective on DiaMedica Therapeutics from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Thursday, June 20th.
In other DiaMedica Therapeutics news, Director Richard D. Pilnik bought 19,000 shares of DiaMedica Therapeutics stock in a transaction dated Friday, May 31st. The stock was bought at an average cost of $2.80 per share, for a total transaction of $53,200.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 12.80% of the company’s stock.
DMAC traded up $0.11 during trading hours on Friday, hitting $3.60. 24,871 shares of the stock were exchanged, compared to its average volume of 60,411. The stock has a 50-day simple moving average of $4.05. DiaMedica Therapeutics has a 12 month low of $2.46 and a 12 month high of $5.93. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.49 and a quick ratio of 10.49.
DiaMedica Therapeutics (NASDAQ:DMAC) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.05). As a group, research analysts anticipate that DiaMedica Therapeutics will post -0.85 earnings per share for the current fiscal year.
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications.
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.